Structural Basis of Malodour Precursor Transport in the Human Axilla

    March 2018
    TLDR The study identified a key protein involved in producing underarm odor and found ways to inhibit it.
    The study identified and determined the crystal structure of a transporter protein for S-Cys-Gly-3M3SH in Staphylococcus hominis, which is involved in producing underarm odor. Using E. coli for genetic manipulation, the researchers conducted transport and functional assays, finding that di- and tripeptides inhibit 3M3SH production, supporting the role of the SH1446 protein as the major transporter. They highlighted the adaptability of the binding site within the POT family of transporters and calculated a turnover number of approximately 10 per minute for the wild-type transporter. The study noted limitations due to the inability to genetically manipulate S. hominis and the need for further verification of the transporter's turnover rate.
    Discuss this study in the Community →

    Related Community Posts Join

    6 / 1000+ results

      community What's your thoughts on Pyrilutamide

      in Product  5 upvotes 1 week ago
      The conversation is about using pyrilutamide and RU58841 as topical solutions to prevent hair loss. Pyrilutamide is considered safer but less potent than RU58841, which some users find effective despite potential side effects like heart palpitations.
      That’s it i’m starting oral Minoxidil

      community That’s it i’m starting oral Minoxidil

      in General  134 upvotes 2 weeks ago
      A 32-year-old man started oral minoxidil at 0.625mg daily, alongside topical minoxidil, to address hair thinning after experiencing side effects from other treatments. He plans to monitor his health closely and adjust the dosage after two months.

      community What’s your views on clascoterone 5% topical solution by cosmo

      in Research/Science  19 upvotes 2 weeks ago
      Clascoterone 5% topical solution shows promise for treating male-pattern hair loss by blocking DHT at the follicle without systemic absorption, potentially offering fewer side effects than oral treatments like finasteride. While results are promising, long-term safety and effectiveness need further study, and it may serve as a starting point for developing more effective treatments.

      community What's going on with hmi115? The Phase 2 was concluded Nov2024 but no news

      in Chat  12 upvotes 2 weeks ago
      Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.
      What’s the best course of action for me? M27

      community What’s the best course of action for me? M27

      in General  123 upvotes 3 weeks ago
      The user is concerned about hair loss and is hesitant to use treatments like finasteride and minoxidil due to potential side effects. Another user suggests gradually introducing finasteride to minimize side effects and maximize results.

    Similar Research

    5 / 1000+ results